Back to Journals » OncoTargets and Therapy » Volume 10

Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status

Total article views   Abstract views HTML views PDF downloads Totals
2,819 Dovepress* 2,239 354+ 844 2,593
PubMed Central* 0 226 126 226
Totals 2,239 580 970 2,819
*Since 18 January 2017
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 2 2

View citations on PubMed Central and Google Scholar